H. Koller (Vienna, Austria), M. Studnicka (Salzburg, Austria), R. Buhl (Mainz, Germany), H. Worth (Furth, Germany)
Effect of fluticasone propionate/salmeterol on exercise endurance in moderate-severe COPD
W. Yang, J. Liu, B. Gao, K. Cheng (Shanghai, China)
|  |
Roflumilast significantly decreased inflammatory biomarkers in induced sputum in current smokers patients with severe chronic obstructive pulmonary disease
A. Sadigov, G. Mammadov, A. Abdullayev (Baku, Azerbaijan)
| |
The pharmacogenetic effect of ADRB2 polymorphisms on therapeutic response in COPD
M. Mustafina, O. Tsvetkova, E. Generozov (Moscow, Russian Federation)
|  |
Ivabradine prevents salbutamol-induced disturbance of cardiac autonomic regulation in patients with chronic obstructive pulmonary disease and coronary heart disease
U. Farhutdinov, R. Zulkarneev, N. Zagidullin, S. Zagidullin, G. Abdrahmanova (Ufa, Russian Federation)
| |
Long term oxygen therapy (LTOT) prescription in chronic obstructive pulmonary disease (COPD) patients in Wigan (northwest England)
S. Gudur, A. Zahar, A. Cross, I. Aziz, A. Ashish (Wigan, United Kingdom)
| |
The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) – Interim report of post-marketing surveillance in Japan
Y. Morioka, T. Hara, H. Kikkawa, H. Hitosugi, P. Yoshida (Tokyo, Japan)
| |
Influence of tiotropium bromide and formoterol on bronchial hyperresponsiveness in COPD
I. Trofimenko, B. Chernyak (Irkutsk, Russian Federation)
| |
Influence of tiotropium bromide (TB) and carbocysteine (C) on mucociliary clearance (MCC) in patients with COPD
T. Pertseva, O. Lykholat, O. Gurzhiy (Dnepropetrovsk, Ukraine)
| |
Microbiological screening infectious exacerbation of chronic obstructive pulmonary disease
O. Dziublyk, N. Nedlinska, O. Mukhin, G. Kapitan, Y. Dziublyk, L. Chechel, V. Kliagin, R. Sukhin (Kiev, Ukraine)
| |
Serum surfactant protein D: Biomarker of chronic obstructive pulmonary disease
C.R. Ju, R.C. Chen (Guangzhou, China)
| |
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD
T. Pertseva, K. Gashynova (Dnipropetrovsk, Ukraine)
| |
Serum surfactant protein D (SPD) as a specific marker for COPD
T. Pertseva, K. Gashynova, O. Bratus, N. Petrik (Dnipropetrovsk, Ukraine)
| |
Effects of endurance training on pulmonary and systemic levels of interleukin-8 in patients with stable COPD
E. Sala, C. Balaguer, F. Renom, A. Ríos, R. Extremera, A. Binimelis, B. Togores, A. Iglesias, J. L. Valera, A. Agustí (Palma Mallorca, Bunyola, Spain)
| |
Antielastin antibodies in chronic obstructive pulmonary disease
B. Nuñez, M.R. Julia, J. Sauleda, A. Clemente, J. García Aymerich, J.M. Anto, A. Agustí, PAC-COPD study group (Palma de Mallorca, Bunyola, Barcelona, Spain)
| |
Oxidative stress parameters correlation with clinical and functional characteristics of COPD patients
V. Kapustina, S. Ovcharenko (Moscow, Russian Federation)
| |
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes?
L. Konopkina, B. Basina, T. Pertseva, V. Berezovskyi, J. Gordienko (Dnipropetrovs‘k, Ukraine)
| |
Adenovirus IgG avidity – A marker of outcome in COPD-exacerbations
L. Boeck, M. Gencay, M. Tamm, M. Christ-Crain, B. Mueller, M. Roth, D. Stolz (Basel, Aarau, Switzerland)
| |
Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities
M. Small, S. Broomfield, R. Pollard, S. Fermer (Macclesfield, United Kingdom)
| |
Effect of melatonin on sleep quality of chronic obstructive pulmonary disease (COPD) patients
A. Halvani, F. Mohsenpour, E. Eshaghieh Firouz Abadi (Yazd, Islamic Republic Of Iran)
| |
Can 6 minute walk test with continuous pulse oximetry predict nocturnal hypoxemia in chronic obstructive pulmonary disease?
M.S. Ali, D. Talwar, R. Singh (Noida, India)
| |